We are delighted to announce that John Menapace has joined the Max Foundation as CFO/VP of Administration.
John brings demonstrated business leadership to his new role with a background comprising more than 20 years of experience in driving growth and profitability, across Fortune 50, Big 5, non-profit, and start-up companies. His prior roles include positions of increasing responsibility within such leading organizations as the American Red Cross, Clinton Health Access Initiative, and Kedrion Biopharma. Most recently, he was CFO of The Floating Hospital in New York, one of New York City’s oldest healthcare charities with over 150 years of service to the neediest New Yorkers.
“I feel privileged to be joining The Max Foundation team,” says John. “Having worked in several charitable organizations, I am familiar with the Max Foundation’s lifesaving mission of acting as a bridge between patients and treatment while focusing on those no one else is helping. I am honored to be a part of this deeply humanitarian effort and look forward to actively supporting and working towards fulfilling our near- and long-term goals.”
“We are at a pivotal period of growth and expansion at the Max Foundation, adds Pat Garcia-Gonzales, CEO of the Max Foundation. “With John’s richly diverse experience including enterprise transformation and creating value across international markets, he is well suited to lead us into this next phase of growth and evolution as we strategically expand our external partnerships and internal talent”.
We’re excited about the depth and caliber of John’s background and look forward to his contributions as we further extend the Max Foundation’s mission of ensuring safe, high-impact medicine for all patients around the globe.
Please join us in welcoming John Menapace to the Max Foundation and wishing him much success.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Max adds three new members to the Board of Directors, increasing the seats from eight to 11 In addition, Max has added 10 new team members in 2024 to support growing patient reach, collaboration with partners, and new disease areas This expansion will ensure Max can meet its strategic goals, including treating more patients, amplifying….
Three women diagnosed with HER2- HR+ advanced breast cancer in Mozambique have begun treatment, with efforts underway to open access in eight additional countries The Max Foundation leading initiative through its Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT) with the goal of increasing access to treatment, care, and support at no cost to….
A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.
